MedTrace Logo

Drug-drug Interaction Study of Rifampin and Anaprazole Sodium

NCT07330531 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-01-09

No results posted yet for this study

Summary

A drug-drug interaction study designed to evaluate the drug-drug interaction between rifampin capsules and anaprazole sodium enteric-coated tablets in healthy adult subjects

Conditions

  • Drug-drug Interaction Study

Interventions

DRUG

Anelazol Sodium Enteric-coated Tablets

60mg QD

DRUG

Rifampicin Capsules

600mg QD

Sponsors & Collaborators

  • Xuanzhu Biopharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Qing Wen, Master · Jinan Central Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-01-04
Primary Completion
2026-02-05
Completion
2027-07-21

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07330531 on ClinicalTrials.gov